Tech Company Financing Transactions
Taibang Biologic Group Funding Round
Taibang Biologic Group, operating out of Beijing, scored $300 million in funding from Abu Dhabi Investment Authority, GIC and China Life Insurance.
Transaction Overview
Company Name
Announced On
8/2/2022
Transaction Type
Venture Equity
Amount
$300,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will be used to finance its expansion of plasma stations and its research and development of new products.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
18th Floor Jialong International Tower No. 19 Chaoyang Park
Beijing, 100125
China
Beijing, 100125
China
Phone
Website
Email Address
Overview
Founded in 2002, Taibang Biologic Group (Taibang) is a leading Chinese biopharmaceutical company that provides a comprehensive range of plasma-derived products. The company's core business includes the development, manufacture and sale of plasma-derived products and other biopharmaceutical products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Chow
Chief Financial Officer
Gary Wang
Executive Vice President
Pang Guangli
VP - Human Resources
Xia Nan
VP - Operations
Yuan Feng
VP - Product Management
Yang Gang
Browse more venture capital transactions:
Prev: 8/2/2022: Milestones venture capital transaction
Next: 8/2/2022: IDRx venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs